公开(公告)号：WO1986001120A1

公开(公告)日：1986-02-27

申请号：PCT/US1985000978

申请日：1985-05-29

Applicant: SURVIVAL TECHNOLOGY, INC.

Inventor： SURVIVAL TECHNOLOGY, INC. ,  SARNOFF, Jay, Stanley

IPC: A61N01/30

CPC classification number: A61K9/0019 ,  A61K31/13 ,  A61K31/415 ,  A61K31/66 ,  A61K33/02 ,  A61K38/446 ,  A61K38/49 ,  A61K47/18 ,  A61M5/19 ,  A61M5/2066 ,  A61M2005/1787 ,  A61M2005/206 ,  A61M2005/2073 ,  A61N1/327 ,  A61N1/36017 ,  A61N1/3756 ,  C12Y115/01001 ,  C12Y304/21068 ,  A61K2300/00

Abstract: A method and apparatus for treating a patient with liquid medicament under circumstances where intravenous injection is not practical but the fast response time of an intravenous injection is desirable, including the treatment of individuals undergoing heart attack symptoms with t-PA. The method comprises the steps of injecting with automatic injector (14) the liquid medicament t-PA, preferably with a blood absorption enhancing agent such as hydroxylamine hydrochloride into the muscle tissue of the patient, applying to the patient which has received the injection repeated blood flow stimulating cylcles generated by circuit (180), each of which includes a period of electrical stimulus during which the muscle tissue which has received the injection tenses followed by a period of no electrical stimulus during which the muscle tissue which received the injection is allowed to relax inducing enhanced blood flow within the muscle tissue, and continuing the application of the repeated blood flow stimulating cycles until the injected liquid medicament has been sufficiently absorbed into the enhanced blood flow to achieve a desired possible patient response of reperfusion and apparatus for carrying out the method.

Abstract translation: 一种在静脉注射不实际的情况下治疗患有液体药物的患者的方法和装置，但需要静脉注射的快速反应时间，包括用t-PA治疗患有心脏病发作症状的个体。 该方法包括以下步骤：将液体药物t-PA自动注射器（14）注射到患者的肌肉组织中，优选用血液吸收增强剂如盐酸羟胺注射到已经接受注射重复血液的患者 由电路（180）产生的流动刺激的圆柱，其中每一个包括电刺激的时段，在此期间已经接收到注射时态的肌肉组织之后是没有电刺激的时间段，在此期间接收注射的肌肉组织被允许 放松引起肌肉组织内的增强的血液流动，并继续施加重复的血液流动刺激循环，直到注射的液体药物已被充分吸收到增强的血液流中，以实现期望的可能的患者对再灌注的反应和用于执行 方法。

公开(公告)号：WO1986001110A1

公开(公告)日：1986-02-27

申请号：PCT/US1985001505

申请日：1985-08-08

Applicant: SURVIVAL TECHNOLOGY, INC.

Inventor： SURVIVAL TECHNOLOGY, INC. ,  SARNOFF, Stanley, Jay

IPC: A61K37/04

CPC classification number: A61K9/0019 ,  A61K31/13 ,  A61K31/415 ,  A61K31/66 ,  A61K33/02 ,  A61K38/26 ,  A61K38/28 ,  A61K38/446 ,  A61K47/18 ,  A61M5/19 ,  C12Y115/01001 ,  A61K2300/00

Abstract: The absorption of a scavenger of oxygen free radicals generated at the time of reperfusion or the absorption of an agent preventing the cytotoxic effects on healthy cells in a mammal, e.g. superoxide dismutase or the compound WR-2721 [H2N(CH2)3NHCH2CH2SPO3H2] is enhanced by substantially simultaneously administering an absorption enhancing agent therefore, e.g. hydroxylamine or a non-toxic salt thereof. It is also part of the invention to inject WR-2721 intravenously or intramuscularly as a scavenger of oxygen free radicals even in the absence of an absorption enhancing agent.

Abstract translation: 在再灌注时产生的氧自由基清除剂的吸收或抑制哺乳动物健康细胞的细胞毒性作用的药剂的吸收，例如， 超氧化物歧化酶或化合物WR-2721 [H 2 N（CH 2）3 NHCH 2 CH 2 SPO 3 H 2]通过基本上同时施用吸收增强剂而增强，因此，例如， 羟胺或其无毒盐。 即使在不存在吸收促进剂的情况下，也注射WR-2721作为氧自由基的清除剂而静脉内或肌内注射WR-2721的一部分。

公开(公告)号：WO1985002775A1

公开(公告)日：1985-07-04

申请号：PCT/US1984002050

申请日：1984-12-14

Applicant: SURVIVAL TECHNOLOGY, INC.

Inventor： SURVIVAL TECHNOLOGY, INC. ,  SARNOFF, Stanley, Jay ,  CALKINS, George, Burnham ,  TARELLO, William, Robert

IPC: A61M05/00

CPC classification number: A61M5/2066 ,  A61M5/19 ,  A61M5/2033 ,  A61M2005/206

Abstract: A plural dosage automatic injector (10) comprising an elongated tubular housing assembly (12) having side by side first and second medicament injecting assemblies (14 and 18) each including a container (48 and 116), a hypodermic needle (56 and 130), a liquid medicament (54 and 128) and a plunger (50 and 126) within the forward end portion thereof and, first and second stressed spring assemblies (16 and 20) in the rearward end portion thereof disposed in operative relation with said first and second medicament injecting assemblies for operating the latter. A manually operable safety device (22) is provided which includes a first safety pin (24) operable (1) when in a safety position with respect to the first spring stressed assembly to prevent actuation and release thereof and (2) when removed from its safety position to permit the actuation and release of the second stressed spring assembly. A mechanical motion transmitting mechanism (28) is provided which is operable to transmit a movement occuring as a result of the actuation and release of the first stressed spring assembly into a secondary acttuating movement operable to (1) effect a relative movement between the automatic safety pin and the second stressed spring assembly sufficient to remove the automatic safety pin from its safety position and (2) thereafter actuate and release second stressed spring assembly to operate the second medicament injecting assembly.